Chemed Reports Second-Quarter 2010 Results

Chemed Corporation (Chemed) (NYSE:CHE), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest provider of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its second quarter ended June 30, 2010, versus the comparable prior-year period, as follows:

Consolidated operating results:

• Revenue increased 6.7% to $315.0 million
• Net Income increased 9.3% to $18.9 million
• Adjusted Net Income increased 3.1% to $22.7 million

VITAS segment operating results:

• Net Patient Revenue of $226.6 million, an increase of 7.3%
• Average Daily Census (ADC) of 12,584, an increase of 5.6%
• Admissions of 14,423, an increase of 4.2%
• Net Income of $18.3 million, an increase of 6.8%
• Adjusted EBITDA of $33.1 million, an increase of 5.6%
• Adjusted EBITDA margin of 14.6%, a decrease of 24 basis points

Roto-Rooter segment operating results:

• Revenue of $88.4 million, an increase of 5.2%
• Job count of 166,848, a decrease of 0.7%
• Net Income of $8.9 million, an increase of 0.7%
• Adjusted EBITDA of $15.1 million, a decrease of 2.8%
• Adjusted EBITDA margin of 17.1%, a decrease of 141 basis points

VITAS

Net revenue for VITAS was $226.6 million in the second quarter of 2010, which is an increase of 7.3% over the prior-year period. This revenue growth was the result of increased ADC of 5.6%, driven by an increase in admissions of 4.2%, combined with Medicare price increases of approximately 1.3%. The remaining growth was driven by geographic mix shift of the patient base.

The 4.2% admissions growth in the second quarter of 2010 compares favorably to the 0.8% decline in admissions in the prior-year quarter and a 0.7% decline in admissions for full-year 2009.

Average revenue per patient per day in the quarter, excluding the impact of Medicare Cap, was $197.89, which is 1.8% above the prior-year period. Routine home care reimbursement and high acuity care averaged $155.33 and $682.40, respectively, per patient per day in the second quarter of 2010. During the quarter, high acuity days of care were 8.1% of total days of care. This is essentially equal to the prior-year quarter.

In the second quarter of 2010, VITAS recorded a net revenue increase of $35,000 due to the reversal of the estimated Medicare Cap limitations recorded for a small program in the first quarter of 2010.

Of VITAS’ 33 unique Medicare provider numbers, 31 provider numbers, or 94%, have a Medicare Cap cushion greater than 10% for most recent twelve-month period. Two provider numbers have Medicare Cap cushion below 5%. VITAS generated an aggregate Medicare Cap cushion of $199 million, or 25%, during the trailing twelve-month period.

The second quarter of 2010 gross margin, excluding the impact of Medicare Cap, was 22.7%, which is 41 basis points lower than the second quarter of 2009. Increased expenses relating to field-based admissions, expansion of inpatient units and increased documentation requirements in Medicare certification all contributed to this margin decline.

Selling, general and administrative expense was $18.4 million in the second quarter of 2010, which is an increase of 2.9% when compared to the prior-year quarter. Adjusted EBITDA totaled $33.1 million in the quarter. Adjusted EBITDA margin, excluding the impact from Medicare Cap, was 14.6% in the quarter which was essentially equal to the prior-year quarter.

Roto-Rooter

Roto-Rooter’s plumbing and drain cleaning business generated sales of $88.4 million for the second quarter of 2010, an increase of 5.2% over the prior-year quarter. Roto-Rooter’s gross margin was 45.2% in the quarter, a 103 basis point decline when compared to the second quarter of 2009. Adjusted EBITDA in the second quarter of 2010 totaled $15.1 million, a decline of 2.8%, and the Adjusted EBITDA margin was 17.1% in the quarter, a decline of 141 basis points, when compared to the prior-year quarter.

Job count in the second quarter of 2010 declined a modest 0.7% when compared to the prior-year period. During the second quarter of 2010, total residential jobs increased 0.7%, as residential plumbing jobs increased 6.6% and residential drain cleaning jobs declined 2.2%, when compared to the second quarter of 2009. Residential jobs represented 72% of total job count in the quarter. Total commercial jobs declined 4.1%, with commercial plumbing job count declining 1.0% and commercial drain cleaning decreasing 5.6% when compared to the prior-year quarter. The "Other” job category declined 2.6%.

Management continues to have discussions with existing franchisees to acquire Roto-Rooter franchise territories. This activity is attributed to the current state of the capital markets, the potential increase in tax rates and the recessionary difficulties our franchisees are experiencing. Management will continue to be highly disciplined in terms of valuation, risk assessment and overall return on investment of any potential acquisition. However, the timing or actual completion of any acquisition cannot be predicted.

Chemed Consolidated Debt and Cash Flows

Chemed had total debt of $155.6 million at June 30, 2010. This debt is net of the discount taken as a result of convertible debt accounting requirements. Excluding this discount, aggregate debt is $187.0 million and is due in May 2014. Chemed’s total debt equates to less than one times trailing twelve-month adjusted EBITDA.

Chemed’s $175.0 million revolving credit facility expires in May 2012. At June 30, 2010, this credit facility had approximately $146.7 million of undrawn borrowing capacity after deducting $28.3 million for letters of credit issued under this facility to secure the Company’s workers’ compensation insurance.

Capital expenditures for the second quarter of 2010 aggregated $6.5 million and compares favorably to depreciation and amortization during the same period of $7.5 million.

Total cash and cash equivalents as of June 30, 2010, was $109.1 million, which represents 44.7% of total current assets. Net cash provided from operations in the second quarter of 2010 aggregated $12.6 million.

The Company increased its quarterly dividend per share in the third quarter of 2009, from $0.06 per share to $0.12 per share. During the second quarter of 2010, the company purchased $6.3 million of treasury stock in the open market and has approximately $45 million of remaining authorization under its previously announced share repurchase program. Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

Guidance for 2010

VITAS expects to achieve full-year 2010 revenue growth, prior to Medicare Cap and BNAF, of 6.0% to 7.0%. Admissions in 2010 are estimated to increase 3.0% to 4.0% and full-year Adjusted EBITDA margin, prior to Medicare Cap, is estimated to be 15.0% to 15.5%. Effective October 1, 2009, Medicare increased average hospice reimbursement rates by approximately 1.3%. Our 2010 full-year guidance includes $2.5 million of estimated Medicare contractual billing limitations for the remaining two quarters of 2010.

Roto-Rooter expects to achieve full-year 2010 revenue growth of 4.0% to 4.5%. The revenue estimate is a result of increased pricing of approximately 3.0%, a favorable mix shift to higher revenue jobs, offset by a job count decline estimated at 2.0% to 4.0%. Adjusted EBITDA margin for 2010 is estimated in the range of 17.5% to 18.5%.

Based upon these factors, an effective tax rate of 39.0% and a full-year average diluted share count of 23.1 million shares, management estimates 2010 earnings per diluted share from continuing operations, excluding non-cash expenses for stock options, the non-cash increase in interest expense related to the accounting change for convertible debt and other items not indicative of ongoing operations will be in the range of $4.05 to $4.20.

Conference Call

Chemed will host a conference call and webcast at 10 a.m., EDT, on Thursday, July 29, 2010, to discuss the Company’s quarterly results and to provide an update on its business. The dial-in number for the conference call is (800) 299-7635 for U.S. and Canadian participants and (617) 786-2901 for international participants. The participant passcode is 77675182. A live webcast of the call can be accessed on Chemed’s website at www.chemed.com by clicking on Investor Relations Home.

A taped replay of the conference call will be available beginning approximately 24 hours after the call’s conclusion. It can be accessed by dialing (888) 286-8010 for U.S. and Canadian callers and (617) 801-6888 for international callers and will be available for one week following the live call. The replay passcode is 40198921. An archived webcast will also be available at www.chemed.com.

Chemed Corporation operates in the healthcare field through its VITAS Healthcare Corporation subsidiary. VITAS provides daily hospice services to approximately 12,000 patients with severe, life-limiting illnesses. This type of care is focused on making the terminally ill patient's final days as comfortable and pain-free as possible.

Chemed operates in the residential and commercial plumbing and drain cleaning industry under the brand name Roto-Rooter. Roto-Rooter provides plumbing and drain service through company-owned branches, independent contractors and franchisees in the United States and Canada. Roto-Rooter also has licensed master franchisees in Indonesia, Singapore, Japan, and the Philippines.

This press release contains information about Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed’s financial performance. In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company’s operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements. Chemed’s management similarly uses EBITDA, Adjusted EBITDA and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies. These measures also help Chemed’s management to estimate the resources required to meet Chemed’s future financial obligations and expenditures. Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. We calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by service revenue and sales. A reconciliation of Chemed’s net income to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is presented in the tables following the text of this press release.

Forward-Looking Statements

Certain statements contained in this press release and the accompanying tables are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "hope," "anticipate," "plan" and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These statements are based on current expectations and assumptions and involve various risks and uncertainties, which could cause Chemed's actual results to differ from those expressed in such forward-looking statements. These risks and uncertainties arise from, among other things, possible changes in regulations governing the hospice care or plumbing and drain cleaning industries; periodic changes in reimbursement levels and procedures under Medicare and Medicaid programs; difficulties predicting patient length of stay and estimating potential Medicare reimbursement obligations; challenges inherent in Chemed's growth strategy; the current shortage of qualified nurses, other healthcare professionals and licensed plumbing and drain cleaning technicians; Chemed’s dependence on patient referral sources; and other factors detailed under the caption "Description of Business by Segment" or "Risk Factors" in Chemed’s most recent report on form 10-Q or 10-K and its other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on such forward-looking statements and there are no assurances that the matters contained in such statements will be achieved.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENT OF INCOME
(in thousands, except per share data)(unaudited)
						Three Months Ended June 30,									Six Months Ended June 30,
						2010				2009					2010				2009
Service revenues and sales						$	314,995			$	295,255				$	623,808			$	590,193
Cost of services provided and goods sold							223,702				207,337					442,839				414,350
Selling, general and administrative expenses (aa)							49,956				49,580					98,494				95,373
Depreciation							6,194				5,338					11,663				10,663
Amortization							1,287				1,618					2,511				3,154
Other operating expenses (bb)							-				3,444					-				3,989
	Total costs and expenses						281,139				267,317					555,507				527,529
	Income from operations						33,856				27,938					68,301				62,664
Interest expense							(2,999	)			(3,142	)				(5,951	)			(5,986	)
Other income--net (cc)							10				3,358					196				3,082
	Income before income taxes						30,867				28,154					62,546				59,760
Income taxes							(12,012	)			(10,904	)				(24,333	)			(23,171	)
Net income						$	18,855			$	17,250				$	38,213			$	36,589
Earnings Per Share
	Net income					$	0.83			$	0.77				$	1.69			$	1.63
	Average number of shares outstanding						22,644				22,417					22,608				22,406
Diluted Earnings Per Share
	Net income					$	0.82			$	0.76				$	1.66			$	1.61
	Average number of shares outstanding						23,080				22,672					23,012				22,660
(aa)	Selling, general and administrative ("SG&A") expenses comprise (in thousands):
						Three Months Ended June 30,									Six Months Ended June 30,
						2010				2009					2010				2009
		SG&A expenses before long-term incentive compensation and the impact of market gains and losses of deferred compensation plans				$	48,240			$	46,381				$	96,590			$	93,788
		Long-term incentive compensation					1,799				-					1,799				-
		Market value gains/(losses) on liabilities held in deferred compensation trusts (cc)					(83	)			3,199					105				1,585
			Total SG&A expenses			$	49,956			$	49,580				$	98,494			$	95,373
(bb)	Amount represents expenses associated with contested proxy solicitation.
(cc)	Other income--net comprises (in thousands):
						Three Months Ended June 30,									Six Months Ended June 30,
						2010				2009					2010				2009
		Interest income				$	150			$	207				$	225			$	289
		Market value gains/(losses) on assets held in deferred compensation trusts					(83	)			3,199					105				1,585
		Loss on disposal of property and equipment					(58	)			(78	)				(152	)			(54	)
		Non-taxable income from certain investments held in deferred compensation trusts					-				-					-				1,211
		Other					1				30					18				51
			Total other income--net			$	10			$	3,358				$	196			$	3,082

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED BALANCE SHEET
(in thousands, except per share data)(unaudited)
							June 30,
							2010					2009
Assets
	Current assets
		Cash and cash equivalents					$	109,080				$	16,632
		Accounts receivable less allowances						101,736					104,123
		Inventories						7,978					8,240
		Current deferred income taxes						14,453					15,911
		Prepaid income taxes						351					5,049
		Prepaid expenses						10,423					9,031
			Total current assets					244,021					158,986
	Investments of deferred compensation plans held in trust							26,282					20,348
	Properties and equipment, at cost less accumulated depreciation							78,437					73,081
	Identifiable intangible assets less accumulated amortization							56,620					59,875
	Goodwill							450,105					450,005
	Other assets							10,498					13,908
				Total Assets			$	865,963				$	776,203
Liabilities
	Current liabilities
		Accounts payable					$	49,131				$	49,471
		Current portion of long-term debt						-					5,070
		Income taxes						4,783					1,301
		Accrued insurance						34,729					35,029
		Accrued compensation						41,613					37,936
		Other current liabilities						11,669					13,876
			Total current liabilities					141,925					142,683
	Deferred income taxes							24,353					23,305
	Long-term debt							155,608					148,763
	Deferred compensation liabilities							25,374					20,157
	Other liabilities							5,736					4,391
				Total Liabilities				352,996					339,299
Stockholders' Equity
	Capital stock							30,202					29,614
	Paid-in capital							351,672					320,629
	Retained earnings							436,098					371,617
	Treasury stock, at cost							(307,003	)				(286,888	)
	Deferred compensation payable in Company stock							1,998					1,932
				Total Stockholders' Equity				512,967					436,904
				Total Liabilities and Stockholders' Equity			$	865,963				$	776,203

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENT OF CASH FLOWS
(in thousands)(unaudited)
					Six Months Ended June 30,
					2010				2009
Cash Flows from Operating Activities
	Net income				$	38,213			$	36,589
	Adjustments to reconcile net income to net cash provided by operating activities:
		Depreciation and amortization				14,174				13,817
		Provision for uncollectible accounts receivable				4,863				5,459
		Stock option expense				4,397				4,485
		Amortization of discount on convertible notes				3,481				3,253
		Provision for deferred income taxes				(2,364	)			317
		Noncash long-term incentive compensation				1,580				-
		Changes in operating assets and liabilities, excluding amounts acquired in business combinations:
		Increase in accounts receivable				(53,169	)			(11,575	)
		Increase in inventories				(435	)			(668	)
		Decrease/(increase) in prepaid expenses				(35	)			902
		Increase/(decrease) in accounts payable and other current liabilities				3,035				(4,005	)
		Increase/(decrease) in income taxes				6,902				(4,267	)
		Decrease/(increase) in other assets				(1,935	)			2,264
		Increase/(decrease) in other liabilities				2,938				(3,481	)
		Excess tax benefit on share-based compensation				(1,802	)			(313	)
		Other sources				434				343
		Net cash provided by operating activities				20,277				43,120
Cash Flows from Investing Activities
	Capital expenditures					(11,942	)			(8,136	)
	Proceeds from sales of property and equipment					89				1,496
	Business combinations, net of cash acquired					(30	)			(1,859	)
	Other uses					(286	)			(475	)
		Net cash used by investing activities				(12,169	)			(8,974	)
Cash Flows from Financing Activities
	Purchases of treasury stock					(10,125	)			(526	)
	Dividends paid					(5,481	)			(2,711	)
	Proceeds from issuance of capital stock					3,475				68
	Excess tax benefit on share-based compensation					1,802				313
	Decrease in cash overdrafts payable					(1,314	)			(781	)
	Repayment of long-term debt					-				(9,599	)
	Net decrease in revolving line of credit					-				(8,200	)
	Other sources					199				294
		Net cash used by financing activities				(11,444	)			(21,142	)
Increase/(Decrease) in Cash and Cash Equivalents						(3,336	)			13,004
Cash and cash equivalents at beginning of year						112,416				3,628
Cash and cash equivalents at end of period					$	109,080			$	16,632

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENT OF INCOME
FOR THE THREE MONTHS ENDED JUNE 30, 2010 AND 2009
(in thousands)(unaudited)
															Chemed
			VITAS				Roto-Rooter				Corporate				Consolidated
2010
Service revenues and sales			$	226,638			$	88,357			$	-			$	314,995
Cost of services provided and goods sold				175,257				48,445				-				223,702
Selling, general and administrative expenses (a)				18,404				24,192				7,360				49,956
Depreciation				4,103				1,950				141				6,194
Amortization				788				132				367				1,287
Total costs and expenses				198,552				74,719				7,868				281,139
Income/(loss) from operations				28,086				13,638				(7,868	)			33,856
Interest expense (a)				(48	)			(64	)			(2,887	)			(2,999	)
Intercompany interest income/(expense)				1,350				773				(2,123	)			-
Other income/(expense)—net				45				14				(49	)			10
Income/(loss) before income taxes				29,433				14,361				(12,927	)			30,867
Income taxes (a)				(11,152	)			(5,501	)			4,641				(12,012	)
Net income/(loss)			$	18,281			$	8,860			$	(8,286	)		$	18,855
2009 (f)
Service revenues and sales			$	211,303			$	83,952			$	-			$	295,255
Cost of services provided and goods sold				162,175				45,162				-				207,337
Selling, general and administrative expenses (b)				17,877				22,844				8,859				49,580
Depreciation				3,256				2,035				47				5,338
Amortization				1,187				117				314				1,618
Other operating expenses (b)				-				-				3,444				3,444
Total costs and expenses				184,495				70,158				12,664				267,317
Income/(loss) from operations				26,808				13,794				(12,664	)			27,938
Interest expense (b)				(326	)			(59	)			(2,757	)			(3,142	)
Intercompany interest income/(expense)				1,023				581				(1,604	)			-
Other income/(expense)—net				123				6				3,229				3,358
Income/(loss) before income taxes				27,628				14,322				(13,796	)			28,154
Income taxes (b)				(10,506	)			(5,524	)			5,126				(10,904	)
Net income/(loss)			$	17,122			$	8,798			$	(8,670	)		$	17,250
The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENT OF INCOME
FOR THE SIX MONTHS ENDED JUNE 30, 2010 AND 2009
(in thousands)(unaudited)
															Chemed
			VITAS				Roto-Rooter				Corporate				Consolidated
2010
Service revenues and sales			$	449,578			$	174,230			$	-			$	623,808
Cost of services provided and goods sold				347,350				95,489				-				442,839
Selling, general and administrative expenses (a)				36,550				48,950				12,994				98,494
Depreciation				7,587				3,901				175				11,663
Amortization				1,559				255				697				2,511
Total costs and expenses				393,046				148,595				13,866				555,507
Income/(loss) from operations				56,532				25,635				(13,866	)			68,301
Interest expense (a)				(80	)			(132	)			(5,739	)			(5,951	)
Intercompany interest income/(expense)				2,639				1,475				(4,114	)			-
Other income/(expense)—net				6				24				166				196
Income/(loss) before income taxes				59,097				27,002				(23,553	)			62,546
Income taxes (a)				(22,378	)			(10,329	)			8,374				(24,333	)
Net income/(loss)			$	36,719			$	16,673			$	(15,179	)		$	38,213
2009 (f)
Service revenues and sales			$	419,720			$	170,473			$	-			$	590,193
Cost of services provided and goods sold				321,807				92,543				-				414,350
Selling, general and administrative expenses (b)				35,423				47,219				12,731				95,373
Depreciation				6,475				4,089				99				10,663
Amortization				2,358				206				590				3,154
Other operating expenses (b)				-				-				3,989				3,989
Total costs and expenses				366,063				144,057				17,409				527,529
Income/(loss) from operations				53,657				26,416				(17,409	)			62,664
Interest expense (b)				(365	)			(94	)			(5,527	)			(5,986	)
Intercompany interest income/(expense)				1,913				1,117				(3,030	)			-
Other income/(expense)—net (b)				120				122				2,840				3,082
Income/(loss) before income taxes				55,325				27,561				(23,126	)			59,760
Income taxes (b)				(21,033	)			(10,534	)			8,396				(23,171	)
Net income/(loss)			$	34,292			$	17,027			$	(14,730	)		$	36,589
The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARY OF EBITDA
FOR THE THREE MONTHS ENDED JUNE 30, 2010 AND 2009
(in thousands)(unaudited)
																	Chemed
					VITAS				Roto-Rooter				Corporate				Consolidated
2010
Net income/(loss)					$	18,281			$	8,860			$	(8,286	)		$	18,855
Add/(deduct):
		Interest expense				48				64				2,887				2,999
		Income taxes				11,152				5,501				(4,641	)			12,012
		Depreciation				4,103				1,950				141				6,194
		Amortization				788				132				367				1,287
		EBITDA				34,372				16,507				(9,532	)			41,347
Add/(deduct):
		Intercompany interest expense/(income)				(1,350	)			(773	)			2,123				-
		Interest income				(90	)			(25	)			(35	)			(150	)
		Expenses of OIG investigation				118				-				-				118
		Expenses of class action litigation				-				105				-				105
		Advertising cost adjustment (c)				-				(678	)			-				(678	)
		Stock option expense				-				-				2,346				2,346
		Long-term incentive compensation				-				-				1,799				1,799
		Adjusted EBITDA			$	33,050			$	15,136			$	(3,299	)		$	44,887
2009 (f)
Net income/(loss)					$	17,122			$	8,798			$	(8,670	)		$	17,250
Add/(deduct):
		Interest expense				326				59				2,757				3,142
		Income taxes				10,506				5,524				(5,126	)			10,904
		Depreciation				3,256				2,035				47				5,338
		Amortization				1,187				117				314				1,618
		EBITDA				32,397				16,533				(10,678	)			38,252
Add/(deduct):
		Intercompany interest expense/(income)				(1,023	)			(581	)			1,604				-
		Interest income				(149	)			(18	)			(40	)			(207	)
		Expenses of OIG investigation				86				-				-				86
		Advertising cost adjustment (c)				-				(368	)			-				(368	)
		Stock option expense				-				-				2,443				2,443
		Expenses associated with contested proxy solicitation				-				-				3,444				3,444
		Adjusted EBITDA			$	31,311			$	15,566			$	(3,227	)		$	43,650
The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARY OF EBITDA
FOR THE SIX MONTHS ENDED JUNE 30, 2010 AND 2009
(in thousands)(unaudited)
																	Chemed
					VITAS				Roto-Rooter				Corporate				Consolidated
2010
Net income/(loss)					$	36,719			$	16,673			$	(15,179	)		$	38,213
Add/(deduct):
		Interest expense				80				132				5,739				5,951
		Income taxes				22,378				10,329				(8,374	)			24,333
		Depreciation				7,587				3,901				175				11,663
		Amortization				1,559				255				697				2,511
		EBITDA				68,323				31,290				(16,942	)			82,671
Add/(deduct):
		Intercompany interest expense/(income)				(2,639	)			(1,475	)			4,114				-
		Interest income				(135	)			(27	)			(63	)			(225	)
		Expenses of OIG investigation				278				-				-				278
		Expenses of class action litigation				-				105				-				105
		Advertising cost adjustment (c)				-				(1,068	)			-				(1,068	)
		Stock option expense				-				-				4,397				4,397
		Long-term incentive compensation				-				-				1,799				1,799
		Adjusted EBITDA			$	65,827			$	28,825			$	(6,695	)		$	87,957
2009 (f)
Net income/(loss)					$	34,292			$	17,027			$	(14,730	)		$	36,589
Add/(deduct):
		Interest expense				365				94				5,527				5,986
		Income taxes				21,033				10,534				(8,396	)			23,171
		Depreciation				6,475				4,089				99				10,663
		Amortization				2,358				206				590				3,154
		EBITDA				64,523				31,950				(16,910	)			79,563
Add/(deduct):
		Intercompany interest expense/(income)				(1,913	)			(1,117	)			3,030				-
		Interest income				(197	)			(36	)			(56	)			(289	)
		Expenses of OIG investigation				99				-				-				99
		Advertising cost adjustment (c)				-				(762	)			-				(762	)
		Stock option expense				-				-				4,485				4,485
		Expenses associated with contested proxy solicitation				-				-				3,989				3,989
		Non-taxable income from certain investments held in deferred compensation trusts				-				-				(1,211	)			(1,211	)
		Adjusted EBITDA			$	62,512			$	30,035			$	(6,673	)		$	85,874
The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
RECONCILIATION OF ADJUSTED NET INCOME
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2010 AND 2009
(in thousands, except per share data)(unaudited)
			Three Months Ended June 30,								Six Months Ended June 30,
			2010			2009 (f)					2010			2009 (f)
Net income as reported			$	18,855		$	17,250				$	38,213		$	36,589
Add/(deduct) after-tax impact of:
Stock option expense				1,484			1,544					2,782			2,836
Additional interest expense resulting from the change in accounting for the conversion feature of the convertible notes				1,068			987					2,115			1,955
Long-term incentive compensation				1,124			-					1,124			-
Expenses of OIG investigation				74			53					173			61
Expenses of class action litigation				63			-					63			-
Expenses associated with contested proxy solicitation				-			2,180					-			2,525
Non-deductible losses and non-taxable gains on investments held in deferred compensation trusts				-			(20	)				-			(756	)
Adjusted net income			$	22,668		$	21,994				$	44,470		$	43,210
Earnings Per Share As Reported
Net income			$	0.83		$	0.77				$	1.69		$	1.63
Average number of shares outstanding				22,644			22,417					22,608			22,406
Diluted Earnings Per Share As Reported
Net income			$	0.82		$	0.76				$	1.66		$	1.61
Average number of shares outstanding				23,080			22,672					23,012			22,660
Adjusted Earnings Per Share
Net income			$	1.00		$	0.98				$	1.97		$	1.93
Average number of shares outstanding				22,644			22,417					22,608			22,406
Adjusted Diluted Earnings Per Share
Net income			$	0.98		$	0.97				$	1.93		$	1.91
Average number of shares outstanding				23,080			22,672					23,012			22,660
The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
OPERATING STATISTICS FOR VITAS SEGMENT
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2010 AND 2009
(unaudited)
						Three Months Ended June 30,								Six Months Ended June 30,
OPERATING STATISTICS						2010				2009				2010				2009
	Net revenue ($000) (d)
		Homecare				$	163,512			$	152,006			$	320,738			$	299,060
		Inpatient					25,989				23,667				52,281				48,759
		Continuous care					37,102				35,125				74,776				69,716
			Total before Medicare cap allowance and 2008 BNAF*			$	226,603			$	210,798			$	447,795			$	417,535
		Estimated BNAF* Accrual Q4 2008					-				-				-				1,950
		Medicare cap allowance					35				505				1,783				235
			Total			$	226,638			$	211,303			$	449,578			$	419,720
	Net revenue as a percent of total before Medicare cap allowance and 2008 BNAF*
		Homecare					72.1	%			72.1	%			71.6	%			71.6	%
		Inpatient					11.5				11.2				11.7				11.7
		Continuous care					16.4				16.7				16.7				16.7
			Total before Medicare cap allowance and 2008 BNAF*				100.0				100.0				100.0				100.0
		Estimated BNAF* Accrual Q4 2008					-				-				-				0.5
		Medicare cap allowance					-				0.2				0.4				-
			Total				100.0	%			100.2	%			100.4	%			100.5	%
	Average daily census ("ADC") (days)
		Homecare					8,345				7,668				8,229				7,573
		Nursing home					3,223				3,292				3,193				3,277
			Routine homecare				11,568				10,960				11,422				10,850
		Inpatient					433				394				438				407
		Continuous care					583				566				594				567
			Total				12,584				11,920				12,454				11,824
	Total Admissions						14,423				13,840				29,267				28,008
	Total Discharges						14,132				13,740				28,685				27,605
	Average length of stay (days)						77.4				73.4				76.6				75.0
	Median length of stay (days)						14.0				14.0				14.0				14.0
	ADC by major diagnosis
		Neurological					32.8	%			32.8	%			32.8	%			32.7	%
		Cancer					18.1				19.2				18.5				19.3
		Cardio					12.0				12.1				11.9				12.2
		Respiratory					6.5				6.6				6.6				6.6
		Other					30.6				29.3				30.2				29.2
			Total				100.0	%			100.0	%			100.0	%			100.0	%
	Admissions by major diagnosis
		Neurological					18.5	%			17.3	%			18.6	%			17.9	%
		Cancer					33.8				35.4				33.8				34.9
		Cardio					11.2				11.9				11.4				12.1
		Respiratory					8.5				7.7				8.5				7.8
		Other					28.0				27.7				27.7				27.3
			Total				100.0	%			100.0	%			100.0	%			100.0	%
	Direct patient care margins (e)
		Routine homecare					52.5	%			52.1	%			51.9	%			51.9	%
		Inpatient					12.3				16.6				13.7				17.1
		Continuous care					21.2				20.2				21.0				20.2
	Homecare margin drivers (dollars per patient day)
		Labor costs				$	52.52			$	51.83			$	53.21			$	52.32
		Drug costs					7.67				7.71				7.72				7.68
		Home medical equipment					6.66				6.82				6.80				6.75
		Medical supplies					2.46				2.36				2.45				2.32
	Inpatient margin drivers (dollars per patient day)
		Labor costs				$	301.81			$	282.46			$	294.27			$	276.96
	Continuous care margin drivers (dollars per patient day)
		Labor costs				$	530.05			$	522.27			$	528.23			$	521.79
	Bad debt expense as a percent of revenues						0.9	%			1.1	%			0.9	%			1.1	%
	Accounts receivable --
	Days of revenue outstanding- excluding unapplied Medicare payments						42.3				55.9				n.a.				n.a.
	Days of revenue outstanding- including unapplied Medicare payments						34.1				36.7				n.a.				n.a.
	* Budget Neutrality Adjustment Factor.
	The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
FOOTNOTES TO FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2010 AND 2009
(unaudited)
(a)		Included in the results of operations 2010 are the following significant credits/(charges) which may not be indicative of ongoing operations (in thousands):
				Three Months Ended June 30, 2010
				VITAS				Roto-Rooter				Corporate				Consolidated
		Selling, general and administrative expenses:
		Expenses of OIG investigation		$	(118	)		$	-			$	-			$	(118	)
		Expenses of class action litigation			-				(105	)			-				(105	)
		Stock option expense			-				-				(2,346	)			(2,346	)
		Long-term incentive compensation			-				-				(1,799	)			(1,799	)
		Interest expense:
		Additional interest expense resulting from the change in accounting for the conversion feature of the convertible notes			-				-				(1,688	)			(1,688	)
		Pretax impact on earnings			(118	)			(105	)			(5,833	)			(6,056	)
		Income tax benefit on the above			44				42				2,157				2,243
		After-tax impact on earnings		$	(74	)		$	(63	)		$	(3,676	)		$	(3,813	)
				Six Months Ended June 30, 2010
				VITAS				Roto-Rooter				Corporate				Consolidated
		Selling, general and administrative expenses:
		Expenses of OIG investigation		$	(278	)		$	-			$	-			$	(278	)
		Expenses of class action litigation			-				(105	)			-				(105	)
		Stock option expense			-				-				(4,397	)			(4,397	)
		Long-term incentive compensation			-				-				(1,799	)			(1,799	)
		Interest expense:
		Additional interest expense resulting from the change in accounting for the conversion feature of the convertible notes			-				-				(3,343	)			(3,343	)
		Pretax impact on earnings			(278	)			(105	)			(9,539	)			(9,922	)
		Income tax benefit on the above			105				42				3,518				3,665
		After-tax impact on earnings		$	(173	)		$	(63	)		$	(6,021	)		$	(6,257	)
(b)		Included in the results of operations 2009 are the following significant credits/(charges) which may not be indicative of ongoing operations (in thousands):
								Three Months Ended June 30, 2009
								VITAS				Corporate				Consolidated
		Selling, general and administrative expenses:
		Expenses of OIG investigation						$	(86	)		$	-			$	(86	)
		Stock option expense							-				(2,443	)			(2,443	)
		Other operating expenses:
		Expenses associated with contested proxy solicitation							-				(3,444	)			(3,444	)
		Interest expense:
		Additional interest expense resulting from the change in accounting for the conversion feature of the convertible notes							-				(1,561	)			(1,561	)
		Pretax impact on earnings							(86	)			(7,448	)			(7,534	)
		Income tax benefit on the above							33				2,757				2,790
		After-tax impact on earnings						$	(53	)		$	(4,691	)		$	(4,744	)
								Six Months Ended June 30, 2009
								VITAS				Corporate				Consolidated
		Selling, general and administrative expenses:
		Expenses of OIG investigation						$	(99	)		$	-			$	(99	)
		Stock option expense							-				(4,485	)			(4,485	)
		Other operating expenses:
		Expenses associated with contested proxy solicitation							-				(3,989	)			(3,989	)
		Interest expense:
		Additional interest expense resulting from the change in accounting for the conversion feature of the convertible notes							-				(3,091	)			(3,091	)
		Other income/(expense) -- net:
		Non-taxable income from certain investments held in deferred compensation trusts							-				1,211				1,211
		Pretax impact on earnings							(99	)			(10,354	)			(10,453	)
		Income tax benefit on the above							38				4,249				4,287
		Income tax impact of non-deductible net market losses on investments held in deferred compensation trusts							-				(455	)			(455	)
		After-tax impact on earnings						$	(61	)		$	(6,560	)		$	(6,621	)
(c)		Under Generally Accepted Accounting Principles ("GAAP"), the Roto-Rooter segment expenses all advertising, including the cost of telephone directories, immediately upon the initial release of the advertising. Telephone directories are generally in circulation 12 months. If a directory is in circulation for a time period greater or less than 12 months, the publisher adjusts the directory billing for the change in billing period. The timing of when a telephone directory is published can and does fluctuate significantly on a quarterly basis. This "direct expensing" results in significant fluctuations in quarterly advertising expense. In the second quarters of 2010 and 2009, GAAP advertising expense for Roto-Rooter totaled $5,501,000 and $5,771,000, respectively. If the expense of the telephone directories were spread over the periods they are in circulation, advertising expense for the second quarters of 2010 and 2009 would total $6,179,000 and $6,139,000, respectively.
		Similarly, for the first six months of 2010 and 2009, GAAP advertising expense for Roto-Rooter totaled $11,236,000 and $11,528,000, respectively. If the expense of the telephone directories were spread over the periods they are in circulation, advertising expense for the first six months of 2010 and 2009 would total $12,304,000 and $12,290,000, respectively.
(d)		VITAS has 5 large (greater than 450 ADC), 19 medium (greater than 200 but less than 450 ADC) and 21 small (less than 200 ADC) hospice programs. There are two programs as of June 30, 2010, with Medicare cap cushion of less than 10% for the most recent 12-month period.
(e)		Amounts exclude indirect patient care and administrative costs, as well as Medicare Cap billing limitation.
(f)		Reclassified to agree with 2010 presentation. Prior to 2010, we recorded stock award amortization as a corporate expense. In the first quarter of 2010, we decided that since this expense was an ongoing expense it should be reported within the appropriate segment. Accordingly, stock award amortization has been allocated to the corresponding business segments for all periods presented.